Transgene, Jennerex Cancer Therapy Improves Survival in Study

Transgene SA (TNG) and Jennerex Biotherapeutics said the high doses of their JX594/TG6006 therapy improved overall survival in advanced liver cancer patients, citing a mid-stage study of 30 patients.

Patients receiving the treatment at the higher dose lived a medial of 13.8 months, compared with 6.7 months for those who received the lower dose, Strasbourg, France-based Transgene and San Francisco-based Jennerex said in an e-mailed statement today. The findings are being presented at the American Association for the Study of Liver Diseases meeting in San Francisco today.

JX594/TG6006 is a virus that is engineered to target and destroy cancerous cells, according to the companies.

To contact the reporter on this story: Kristen Hallam in London at khallam@bloomberg.net

To contact the editor responsible for this story: Phil Serafino at pserafino@bloomberg.net

Press spacebar to pause and continue. Press esc to stop.

Bloomberg reserves the right to remove comments but is under no obligation to do so, or to explain individual moderation decisions.

Please enable JavaScript to view the comments powered by Disqus.